Today we are announcing that we have formed an exclusive partnership with Aptar Pharma to commercialise and promote our Quattrii DPI platform.
We will work really closely with Aptar to bring our novel DPI technology to market and support pharmaceutical companies who need an inhaler that is capable of delivering carrier-based or API-only low-potency formulations of between 50 - 150 mg fill mass.
For carrier-based formulations, the blister-based Quattrii engine can classify and retain nearly all of the lactose carrier within the blister, while delivering a high percentage of the API to the deep lung. By only delivering the fraction of the formulation that is beneficial to the patient, this allows significantly larger doses to be delivered in a single inhalation maneuver, while avoiding cough. This is in contrast to a capsule-based inhaler, which evacuates the entire contents of the carrier fraction, predominantly into the patient's mouth and throat. As such, the same dose would need to be split into multiple inhalations to avoid cough.
Alternatively, Quattrii can also be configured for API-only formulations, enabling it to evacuate the entire blister and deliver a high fine particle dose.
We are really excited by this development and look forward to talking to the pharmaceutical industry at DDL 2024 next month.
Here is the official announcement from Aptar:
Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of its Quattrii Dry Powder Inhaler (DPI) platform. Under this agreement, Aptar Pharma will provide comprehensive support to CHI, serving as the primary point of contact for customers, preparing for commercial manufacture and integrating Aptar’s comprehensive suite of pharmaceutical services to accelerate the growth of the Quattrii DPI platform.
The Quattrii platform offers a unique solution for delivering medium to high payloads of formulation to the lungs. Its blister piercing array generates a specific airflow that allows the classification of the powder: the larger carrier particles are retained within the blister, enabling the patient to inhale only the active ingredient. Alternatively, the array can be adjusted to effectively sweep up all of the powder. This flexibility and efficacy in the entrainment and aerosolization of the powder produces a lower risk of cough and enhanced deep lung deposition.
Howard Burnett, Vice President, Global Pulmonary Category, Aptar Pharma, stated, “The CHI team brings deep knowledge, experience and innovation to the dry powder inhaler landscape. Aptar Pharma is very pleased to offer the Quattrii technology in partnership with CHI’s expertise. This enables us to be able to provide full support from our portfolio of services to all drug developers, from formulation development to patient onboarding.”
David Harris, co-founder & CEO of CHI, stated, “We are really excited to be partnering with Aptar Pharma to bring our Quattrii DPI platform to market. Through this relationship, Aptar’s pharmaceutical customers will now have access to a next-generation DPI platform capable of delivering high doses of low-potency molecules. This will open up a wide range of opportunities for improved patient outcomes across many new and existing conditions.”
This collaboration further strengthens Aptar Pharma’s leadership in respiratory by offering a broader range of drug delivery formats, solutions and services. By leveraging offerings within Aptar Pharma companies such as Nanopharm’s formulation development and analytical expertise, Noble’s Human Factors support and patient onboarding, and Aptar Digital Health’s services, Aptar Pharma can customize drug formulation development, optimize device design and differentiate with improved patient outcomes to provide their customers with a value-added finished product.
About Cambridge Healthcare Innovations
CHI is a Cambridge-based medical device company that was born of shared determination to force progress into the field of respiratory medicine. Before CHI was created, the team worked at many of the medical device development consultancies based in and around Cambridge, UK. They found themselves growing frustrated as they were working on making incremental improvements to a form of technology – the inhaler – which hadn’t changed fundamentally in decades.
With their deep understanding of aerosol physics, fluid dynamics, and lung characteristics - along with decades of experience in medical device development - they knew that there was immense room for improvement in DPI technology, which would not only transform the treatment of asthma and COPD, but open up the possibility of treating new therapy areas previously inaccessible to respiratory medicine. For more information, visit www.chi.uk.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.